Only first 10,000 results will be saved in the file.
No item is selected. Use checkboxes to select search results.
Displaying 451-475 of 1083 results.
{{ selectedCountPage }} items selected on this page,{{ selectedCountPage }} item selected on this page,{{ selectedCountTotal }} item in total{{ selectedCountTotal }} items in total
Study aim:
Evaluation of the effectiveness of inhaled ethanol therapy in the control of Covid-19 disease
Design:
Phase 3 clinical trial with a control group, parallel and single-blind type, in which the patient remains unaware of the name of the intervention drug.
Random sampling on 86 patients.
Settings
Study aim:
Examining the effects of different exercise modalities in patients with Covid-19
Design (...) .
Settings and conduct:
Laboratory-confirmed COVID-19 patients, Tehran, single-blind, randomization will be (...) exclusion criteria:
Laboratory-confirmed COVID-19 patients.
Inclusion criteria: Tendency and ability to
Study aim:
Determining the effect of FLUVAR® nebulizer on increasing blood oxygen saturation and reducing dyspnea in COVID-19 patients
Design:
Phase 2 of two-stage multicenter clinical trial, first stage on 30 COVID19 patients admitted to emergency department in 2 randomized groups of drug and placebo
Study aim:
Determination of safety and efficacy of Sakarya-20 inhalation solution as antiviral therapy in COVID-19 patients
Design:
This study is a pilot single assignment clinical trial and add-on (...) . The patients who refer to the emergency department of Azad University hospitals due to COVID-19
to standard of care in out patients patients with mild COVID-19
Design:
This is a parallel 2-arm (...) drugs, 1 month ago drugs Has received antiviral for Covid-19, is pregnant or lactating, has ESRD (...) CVA, etc., are excluded.
Intervention groups:
360ligible patients with mild COVID-19 in a 1:1 ratio
) on anxiety of home quarantine patients with Covid19.
Design:
The present study will be performed as (...) trial with the participation of 60 patients with Covid19. After dividing the research units into (...) patients with Covid-19 according to the schedule. Each training message is sent to individuals twice a week
and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in moderate to severe COVID-19 patients (...) efficient treatment for COVID-19. All study procedures will be conducted at Rasool-E-Akram general hospital (...)
Exclusion criteria: Negative COVID-19 specific PCR test result
Intervention groups:
Patients are divided
patients with Covid19 infection, hospitalized in Hajar Hospital, Shahrekord University of Medical Sciences
Design:
This double-blind clinical trial study will be performed on 80 patients with Covid19 confirmed (...) sequelae of Covid virus 19 follow-up for clinical signs of fever, chills, shortness of breath, breathing
Covid-19
Design:
Clinical trial with control group, with parallel groups, not blind, randomized, phase (...) to receiving the prescribed drugs for the treatment of Covid-19 disease, receives the posterior (...) drugs for the treatment of Covid-19 disease according to the protocol of the Ministry of Health.
Main
of patients with COVID-19
Design:
Clinical trial with control group, with parallel, randomized (...) .
Participants/Inclusion and exclusion criteria:
Inclusion criteria: Hospitalized patients suspected to COVID-19(...) plus typical radiographic sing of COVID-19 that is difficult to justify their symptoms based on other
of COVID-19 disease symptoms
Design:
Clinical trial with parallel control group, non-blinded (...) .
Participants/Inclusion and exclusion criteria:
Inclusion criteria:
Diagnosis of COVID-19
Age 18-65
Having (...) take anticoagulants
Intervention groups:
The intervention group includes patients with COVID-19
Study aim:
Determining the effect of melatonin on improving the symptoms of patients with COVID-19(...) intensive care unit of Vali-e-Asr Hospital of Birjand with a diagnosis of COVID-19. All of the steps will be (...) :
Inclusion criteria: Age 18 to 75 years; Diagnosis of COVID-19 in the last 24 hours; One of the three
and fatigue in patients with COVID-19
Design:
A clinical trial with a control group with parallel (...) randomization.
Settings and conduct:
Patients with Covid-19 are identified through health centers dedicated to (...) years who have been diagnosed with Covid-19 disease by PCR or CT scan of the lung and have symptoms of
with Covid-19 in Isfahan province in 1399
Design:
Clinical trial with control group, with parallel (...)
Study community:
Patients hospitalized with Covid-19 with pulmonary involvement in Khorshid Hospital in (...)COVID-19 on CT scan
Criteria for non-entry
Having comorbidities (chronic kidney failure, cirrhosis
in patients with Covid19
Design:
Clinical trial with control group, with parallel groups, double-blind, randomized, on 48 patients with Covid19, Randomization will be done with block random sampling
Settings and conduct:
This study will be performed in 48 patients with Covid-19 in Shahid Jalil Hospital in
duration of hospitalization in outpatients with COVID-19
Design:
Clinical trial with control group (...) addition to the standard treatment.
Settings and conduct:
COVID-19 positive rapid test patients referred (...)COVID-19 positive rapid test or RT-PCR age >5 years and weight >15 kg are included in the study
the length of hospital stay of patients with Covid-19
Design:
A phase 2 clinical trial with control (...) from patients with COVID-19 based on inclusion criteria and patients will be randomly divided into two (...) criteria:
Male or female patients aged 18 to 75 years with COVID-19 who have been diagnosed by PCR or
life in COVID-19 patients with one-month follow-up
Design:
Clinical trial with parallel control group, randomized, on 40 patients
Settings and conduct:
The COVID-19 wards of Imam Khomeini Hospital in Sari were (...) .
Participants/Inclusion and exclusion criteria:
Inclusion criteria: patients with COVID-19 and under 75 years of
Study aim:
Efficacy and safety of adding Fluoxetine and placebo to the therapeutic regimen of patients with corona virus disease (COVID19) pneumonia.
Design:
Phase 3, double blinded clinical trial with parallel groups on 72 patients. Randomization method is block randomization, using the Random allocation software
Settings and conduct:
After evaluation and getting informed consent, patients will be randomly divided into intervention and placebo groups. Throughout the study, they will be assessed for clinical, laboratory and psychiatric signs and symptoms. Aside from nationally approved regimen, they will either receive Fluoxetine ( 10mg for 4 days followed by 20mg for 24 days) or the similar looking placebo, placed in coded bottles by the pharmacist of the group and so, all other participants are blinded.
Participants/Inclusion and exclusion criteria:
Inclusion criteria
1.16-65 years old patients with established corona virus disease, hospitalized in non critical wards
2.Patient's consent to participate in the study
Exclusion criteria
1.Severe medical or psychiatric disorders or obesity
2.History of psychotropic medication use in the past 2 months or substance use
3.Pregnancy
Intervention groups:
The intervention will start with adding 10 mg Fluoxetine per day to the fixed anti corona regimen for the first 4 days, followed by 20 mg Fluoxetine for the rest of the 4 weeks. The placebo group will receive similar looking placebo for the same amount of time.
Main outcome variables:
Blood oxygen saturation; Number of days of hospitalization; The Need for intubation; ICU admission; Death
Participants/Inclusion and exclusion criteria:
inclusion criteria:
confirmed COVID-19 infection with Lab tests not considering sign and symptoms suspected COVID-19; infection based on national protocol include the
quality in patients with COVID-19
Design:
Clinical trial with control and intervention groups, single (...) performed on patients with Covid-19 hospitalized in the infectious ward of Afzalipour Hospital in Kerman.The (...) : Approved patients with Covid-19, Physical and mental ability to answer questions, Ability to understand and
Study aim:
Evaluation of the effectiveness of microemulsion containing extracted squalene for the treatment of COVID-19
Design:
A clinical trial with a control group, with parallel groups, double-blind (...) and exclusion criteria:
Patients with COVID-19 who have been confirmed by CT scan and have no
Study aim:
Evaluation of the effectiveness of Portulaca Oleracea extract on the clinical COVID-19(...) software.
Settings and conduct:
Patients who have Covid19 (RT-PCR confirmation) and have referred to the (...) :
Outpatients with PCR-approved Covid-19 with 90% oxygen have no underlying disease and are not pregnant or
criteria:
Entry conditions included: 60 to 75 years old/ No history of covid-19 disease in oneself or (...) themselves against covid-19 disease, and people in the control group will be taught how to increase the
with COVID-19 admitted to Shiraz hospitals
Design:
Randomized clinical trial with control group (...) and conduct:
The study site is Shiraz hospitals which is selected for patients with Covid-19. The (...) pneumonia (pneumonitis) caused by COVID19; Patients are not in the severe group and do not need care in